Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 271 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 2 Interventional Results available

Rapid Antidepressant Effects of Leucine

NCT03079297
Conditions
Major Depressive Disorder
Interventions
L-Leucine, Maltodextrin
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Completed Not applicable Interventional Results available

A Trial of SAMe for Treatment-Resistant Bipolar Depression

NCT00762268
Conditions
Bipolar Disorder, Depression, Bipolar Depression
Interventions
SAMe, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Interventions
Spaced Transcranial Direct Current Stimulation (tDCS), Sham Spaced tDCS
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Diego, California
Available No phase listed Expanded access

NRX-101 Expanded Access

NCT05779267
Conditions
Treatment-Resistant Depression
Interventions
NRX-101, Transcranial Magnetic Stimulation Sham
Drug · Device
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Depression
Interventions
Magnesium sulfate
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Completed Not applicable Interventional Results available

Intensive TMS for Bipolar Depression

NCT05228457
Conditions
Bipolar Depression, Treatment Resistant Depression
Interventions
Intensive intermittent theta-burst stimulation (iTBS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Redlands, California • San Diego, California • Marietta, Georgia + 4 more
Active, not recruiting Not applicable Interventional

CET- REM (Correlating ECT Response to EEG Markers)

NCT04451135
Conditions
ECT, Treatment Resistant Depression
Interventions
Electroencephalographic (EEG), Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), Ictal Electroencephalographic (EEG) Measurements, Post-Ictal Electroencephalographic (EEG) Suppression Measurements
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Percept PC DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Conditions
Major Depressive Disorder
Interventions
Motif XCS System
Device
Lead sponsor
Motif Neurotech, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • Houston, Texas
Conditions
Depression, Depressive Disorder
Interventions
Cortical Stimulation, Sham
Device
Lead sponsor
Northstar Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Active, not recruiting Not applicable Interventional

DBS for TRD With the Medtronic Summit RC+S

NCT04106466
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Summit RC+S DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions
MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation
Device · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
25 Years to 64 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Conditions
Refractory Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Baltimore, Maryland
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia